Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell ...

Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, ...

(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

The FDA is having second thoughts about the broad labels it has granted PD-1 inhibitors in newly diagnosed stomach cancer, questioning whether restrictions should be placed on products from Bristol ...